Drug Discovery
Lantern Pharma Receives FDA Guidance for Pediatric CNS Cancer Trial, Advancing AI-Driven Oncology Treatment
Lantern Pharma has completed a Type C meeting with the FDA, gaining regulatory guidance for its planned pediatric trial targeting CNS cancers including ATRT, which could accelerate development of its AI-driven oncology therapy LP-184/STAR-001.
Oncotelic Therapeutics Advances Cancer Pipeline with Phase 3 Candidate and AI Integration
Oncotelic Therapeutics is progressing its RNA-based immunotherapy OT-101 through Phase 3 trials for pancreatic cancer while leveraging strategic partnerships and proprietary AI technology to accelerate drug development across multiple underserved disease areas.
CD BioGlyco Expands Glycobiology Research Capabilities with Custom Glycoconjugate Synthesis Service
CD BioGlyco's new custom glycoconjugate synthesis service enables researchers to study glycan functions in cell recognition and immune responses, advancing biomedical research capabilities.
New Study Offers Hope for Pediatric Glioma Treatment
A collaborative study between the Broad Institute and the Dana-Farber Cancer Institute has identified a promising treatment approach for pediatric gliomas using FDA-approved inhibitors.
Creative Biolabs Introduces AI-Powered Solution to Revolutionize Drug Discovery
Creative Biolabs has launched an AI-powered end-to-end drug discovery solution aimed at addressing the challenges of high costs, failure rates, and lengthy timelines in drug R&D.
Annovis Bio Inc. Secures Comprehensive Patent Coverage for Buntanetap, Enhancing Treatment Prospects for Neurodegenerative Diseases
Annovis Bio Inc. has expanded its patent portfolio to cover a new crystalline form of buntanetap, promising improved stability and bioequivalence for treating neurodegenerative diseases like Alzheimer's and Parkinson's, with protection extending through 2046.
Lantern Pharma Inc. Unveils AI Tool to Predict Cancer Drug Combination Efficacy
Lantern Pharma Inc. introduces an AI-powered module to predict the effectiveness of cancer drug combinations, marking a significant advancement in personalized oncology treatment.
NanoViricides' NV-387 Emerges as Potential Breakthrough in Combatting Measles Outbreaks
NanoViricides Inc. announces its drug candidate NV-387 could significantly impact the treatment of measles, addressing a critical gap in antiviral medications amid rising global outbreaks.
Creative Biolabs Advances Single-Domain Antibody Solutions to Meet Therapeutic Demands
Creative Biolabs is enhancing the development of single-domain antibodies (sdAbs), offering innovative solutions for oncology, neurology, and infectious diseases, highlighting their potential to revolutionize treatment approaches.
Soligenix Inc. Advances in Oral Mucositis Treatment with SGX942
Soligenix Inc. is making strides with SGX942, a novel treatment for severe oral mucositis, showing promise in reducing the condition's severity and duration in cancer patients.
Akari Therapeutics CEO Unveils Novel ADC Platform Targeting Cancer Resistance
Akari Therapeutics, under CEO Abizer Gaslightwala, is pioneering a novel ADC platform aimed at overcoming cancer resistance and enhancing treatment durability through immune system activation.
Creative Biolabs Enhances Cell Therapy Research with Advanced iPSC and Macrophage Solutions
Creative Biolabs introduces innovative tools and services for iPSC neural differentiation and macrophage isolation, significantly advancing cell therapy research and disease modeling.
Lantern Pharma Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL
Lantern Pharma's LP-284 shows promising results in a Phase 1 trial for aggressive DLBCL, marking a significant step forward in the treatment of refractory lymphomas.
Creative Biolabs Advances Precision Medicine with Dual 3D Organoid and Tissue Slice Models
Creative Biolabs is enhancing precision medicine research by integrating 3D organoid and precision-cut tissue slice models, offering a more accurate and efficient approach to drug testing and disease modeling.
Lantern Pharma Engages IBN for Corporate Communications Strategy Amid AI-Driven Oncology Pipeline Advancements
Lantern Pharma partners with IBN to enhance investor awareness as it progresses its AI-driven oncology pipeline, including therapies for lung, brain, breast, and blood cancers.
Quantum BioPharma Submits MS Drug Candidate to UK's ILAP Program
Quantum BioPharma Ltd. advances its multiple sclerosis treatment, Lucid-MS, through the UK's Innovative Licensing and Access Pathway, aiming to accelerate patient access to this innovative therapy.
InFlectis BioScience's IFB-088 Shows Promise in ALS Treatment Through Groundbreaking Study
InFlectis BioScience's study on IFB-088 demonstrates potential in addressing TDP-43 proteinopathy, offering hope for ALS patients by improving motor neuron survival and function.
Lantern Pharma Inc. Harnesses AI to Revolutionize Oncology Drug Development
Lantern Pharma Inc. (NASDAQ: LTRN) is utilizing its AI-driven RADR(R) platform to accelerate the development of precision cancer therapies, marking a significant advancement in oncology drug discovery.
Chemify Unveils World's First Chemputation Facility in Glasgow, Revolutionizing Molecular Design
Chemify's launch of the first Chemifarm in Glasgow marks a significant advancement in molecular design and synthesis, leveraging AI and robotics to accelerate drug discovery and materials science.
Telomir Pharmaceuticals Reports Significant Preclinical Breakthrough with Telomir-1 in Wilson’s Disease Model
Telomir Pharmaceuticals' preclinical data reveals Telomir-1's potential to reverse symptoms of Wilson’s disease, a rare copper accumulation disorder, marking a significant step towards human trials and offering hope for patients.
Pacylex Pharmaceuticals Showcases Promising NMT Inhibitors at BIO Annual Meeting
Pacylex Pharmaceuticals Inc. highlights its innovative N-myristoyltransferase inhibitors (NMTis) at the BIO International Convention, showcasing potential breakthroughs in cancer treatment through oral zelenirstat and ADC payloads.
Tevard Biosciences Appoints Dr. Elisabeth Gardiner as Chief Scientific Officer to Advance tRNA-Based Therapies
Tevard Biosciences has appointed Dr. Elisabeth Gardiner as its new Chief Scientific Officer, marking a significant step in advancing its tRNA-based therapies for genetic diseases, with implications for treating conditions like Duchenne Muscular Dystrophy and TTN-related dilated cardiomyopathy.
Soligenix's HyBryte(TM) Offers New Hope for CTCL Patients with FDA Orphan Drug Designation
Soligenix Inc. advances in the treatment of Cutaneous T-cell lymphoma (CTCL) with HyBryte(TM), a photodynamic therapy showing promise in clinical trials and receiving Orphan Drug Designation, addressing a critical need for effective therapies in this rare disease.
Researchers Uncover Surprising Flexibility in Key Metabolic Enzyme Complex
A groundbreaking study reveals the dynamic structure of the pyruvate dehydrogenase complex, showing unprecedented flexibility that challenges previous understanding of cellular energy production. The research provides critical insights into metabolic processes with potential implications for disease treatment.
Lantern Pharma Shows Promise in Pediatric Brain Cancer Treatment
Lantern Pharma's experimental drug LP-184 demonstrates significant potential in treating atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive pediatric brain cancer, with preclinical studies showing remarkable improvements in survival rates.
Telomir Pharmaceuticals Reveals Promising Vision Restoration in Preclinical AMD Study
Telomir Pharmaceuticals has demonstrated its oral therapeutic candidate Telomir-1 can restore vision and reverse retinal degeneration in a zebrafish model of age-related macular degeneration, highlighting potential breakthrough treatment for vision loss.
NanoViricides Reveals Breakthrough Antiviral Platform at BIO International Convention
NanoViricides will showcase its novel NV-387 broad-spectrum antiviral drug candidate, which demonstrates promising preclinical efficacy against multiple viral infections, potentially revolutionizing viral treatment approaches.
CD BioSciences Advances Aging Research with Customizable Mouse Models
CD BioSciences has developed highly customizable mouse models for aging research, offering pharmaceutical and biotech companies precision tools to accelerate drug discovery and understand age-related diseases more effectively.
Soligenix Develops Novel Therapy to Address Antibiotic-Resistant Bacterial Infections
Soligenix's SGX943 represents a potential breakthrough in combating antibiotic-resistant bacteria, offering a novel broad-spectrum therapy that could help address a critical public health challenge.
Telomir Pharmaceuticals Reveals Innovative Silver(II) Antimicrobial Drug Candidate
Telomir Pharmaceuticals has developed Telomir-Ag2, a novel Silver(II) complex with broad-spectrum antimicrobial properties targeting significant medical markets including wound care and infection treatment.